{"product_id":"crdf-ansoff-analysis","title":"(CRDF) Cardiff Oncology, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Cardiff Oncology, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification and is designed for strategy, investment, or research use. The page includes a real preview\/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to download the complete, ready-to-use Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnvansertib lead-asset prioritization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is clearly using onvansertib as its 1 lead asset, so this is a pure market penetration move in its current oncology niche. By concentrating capital and trial execution on the same program, the company deepens focus on its most advanced asset and lowers dilution across the pipeline. That matters because the value driver is not breadth; it is faster readouts and stronger clinical conviction in one program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMetastatic colorectal cancer trial focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. keeps onvansertib centered on metastatic colorectal cancer, its most visible anti-cancer use and a disease area where it already has clinical data. This market focus deepens its presence in a known oncology segment instead of spreading spend across new indications. With colorectal cancer causing about 53,000 U.S. deaths a year, mCRC remains a large unmet-need market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTROV-054 colorectal combination work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTROV-054’s Phase 1b\/2 work with FOLFIRI and bevacizumab keeps Cardiff Oncology, Inc. in the same colorectal cancer market, instead of chasing a new one. That supports market penetration because the combo targets the current treatment setting where FOLFIRI-based regimens remain a common backbone. If the study shows tolerable safety and added response, it can strengthen Cardiff Oncology, Inc.’s relevance in a market with high unmet need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePLK target emphasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. keeps its market penetration play tightly centered on PLK biology, with PLK1 as the core target and related PLK pathways reinforcing the same scientific lane. That consistency helps the Company stay recognizable in oncology research and deepen its position in the same niche. With one lead asset, onvansertib, the strategy is about sharper share of attention, not broader scope.\u003c\/p\u003e\n\u003cp\u003eThis focus matters because PLK-driven programs are still a narrow field, so every positive data set can strengthen Cardiff Oncology, Inc.'s identity with investigators and partners. In a pre-revenue model, deeper penetration comes from repeated proof in the same mechanism, same tumor settings, and same clinical story. If the PLK signal stays clean, the Company can keep building credibility without changing lanes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePLK1 remains the anchor target.\u003c\/li\u003e\n\u003cli\u003eOne mechanism supports brand clarity.\u003c\/li\u003e\n\u003cli\u003eSame niche, deeper clinical presence.\u003c\/li\u003e\n\u003cli\u003ePre-revenue focus favors specialization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-stage oncology concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is still a clinical-stage oncology company, so market penetration is about moving its current programs through trials, not selling an approved drug. With no commercial launch reported, share gains depend on execution in lead studies, data readouts, and investor visibility in KRAS-mutant and other oncology niches. That makes trial speed and quality the main penetration lever.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical-stage only\u003c\/li\u003e\n\u003cli\u003eNo commercial launch\u003c\/li\u003e\n\u003cli\u003ePenetration = trial execution\u003c\/li\u003e\n\u003cli\u003eVisibility in oncology niches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiff Oncology Bets on Focused Growth in mCRC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is using market penetration by staying tightly focused on onvansertib in metastatic colorectal cancer, where the Company is already building clinical data and investigator familiarity. With about 53,000 U.S. deaths a year from colorectal cancer, the same niche still offers room to deepen share of attention. The play is trial execution, not product breadth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead asset\u003c\/td\u003e\n\u003ctd\u003eOnvansertib\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain niche\u003c\/td\u003e\n\u003ctd\u003emCRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. CRC deaths\u003c\/td\u003e\n\u003ctd\u003e~53,000\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy\u003c\/td\u003e\n\u003ctd\u003eSame market, deeper focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Cardiff Oncology, Inc.’s business growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Cardiff Oncology Ansoff Matrix view to simplify growth strategy decisions and reduce planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources that validate Cardiff Oncology growth assumptions across products and markets for fast, traceable Ansoff analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnvansertib beyond metastatic colorectal cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is pushing onvansertib beyond metastatic colorectal cancer into other oncology settings, so the same molecule can serve larger patient pools without changing the core asset. The company says it is being investigated across several cancer programs, which widens the addressable market and reduces reliance on one indication. That matters because mCRC is only one slice of the global oncology market, which topped $200 billion in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCY140 in solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCY140 is in Phase 1\/2 studies for solid tumors, so Cardiff Oncology, Inc. is moving beyond colorectal cancer into a broader oncology market. That is a classic market development move: one internal pipeline platform, a new disease category. In a U.S. solid-tumor market with millions of new cases each year, even early clinical proof can widen the addressable base fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCY140 in leukemias\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCY140 in leukemias gives Cardiff Oncology, Inc. access to a separate hematologic-cancer market, beyond solid tumors and colorectal cancer. In the U.S., the American Cancer Society projected about 62,000 new leukemia cases and 23,000 deaths for 2025, so even one asset can address a large new patient pool. That broadens CY140’s commercial reach without changing the core program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTROV-053 in metastatic castration resistant prostate cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTROV-053 in metastatic castration-resistant prostate cancer moves Cardiff Oncology, Inc. beyond colorectal cancer into a distinct solid-tumor market. The American Cancer Society estimated 313,780 U.S. prostate cancer cases and 35,770 deaths in 2025, so the program adds real pipeline breadth with an existing clinical asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew therapeutic population\u003c\/li\u003e\n\u003cli\u003eDistinct oncology market\u003c\/li\u003e\n\u003cli\u003eExisting clinical program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePLK platform expansion across cancer types\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardiff Oncology is using the same PLK1 platform across multiple cancers, so the move fits market development: one mechanism, more tumor types. The company’s pipeline spans several solid-tumor settings, which can widen clinical reach without rebuilding the science from scratch. That matters because PLK1 targets a known cell-division pathway already validated in oncology.\u003c\/p\u003e\n\u003cp\u003eAs of the latest public disclosures, Cardiff Oncology reported no product revenue and continued to fund these trials with its cash balance and equity raises, so expansion is still a development-stage bet. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame PLK1 platform, new cancers\u003c\/li\u003e\n\u003cli\u003eBroader clinical footprint\u003c\/li\u003e\n\u003cli\u003eLower scientific reinvention risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiff Oncology Expands PLK1 Reach Into Leukemia and Prostate Cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is extending onvansertib and CY140 into new cancer markets, so the same PLK1 platform can reach more patients without changing the core drug logic. That is classic market development. In 2025, U.S. leukemia cases were projected at about 62,000 and prostate cancer cases at 313,780, which shows the size of the added pools.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003e2025 U.S. size\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCY140\u003c\/td\u003e\n\u003ctd\u003eLeukemia\u003c\/td\u003e\n\u003ctd\u003e62,000 cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTROV-053\u003c\/td\u003e\n\u003ctd\u003emCRPC\u003c\/td\u003e\n\u003ctd\u003e313,780 cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCardiff Oncology, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCY140 next generation PLK inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is using CY140 as a clear product development move: it targets PLK1, PLK2, and PLK3, while onvansertib is a selective PLK1 inhibitor. That makes CY140 a distinct oncology asset, not just a line extension. In Ansoff terms, this is new product development in an existing cancer market, with 3 PLK isoforms in scope.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTROV-054 combination regimen development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTROV-054 is a new combination regimen, not a stand-alone legacy drug, because Cardiff Oncology, Inc. is studying it with FOLFIRI and bevacizumab in colorectal cancer. Metastatic colorectal cancer is a large target, with about 1.9 million new cases worldwide in 2022, so regimen design can drive new use faster than a new molecular entity. This fits product development in the Ansoff Matrix: same market, new therapeutic mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTROV-053 Zytiga combination development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTROV-053 is being tested with Zytiga in metastatic castration-resistant prostate cancer, turning an existing therapy into a new combo product. This is a product-development move in a large market: prostate cancer causes about 35,000 U.S. deaths a year, and mCRPC remains a hard-to-treat setting. Cardiff Oncology, Inc. is trying to lift clinical value without changing the disease area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOnvansertib anti cancer expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOnvansertib is Cardiff Oncology, Inc.'s lead asset and is being tested in several anti-cancer settings, mainly solid tumors. That is classic product development: one molecule, more use cases, still inside oncology. It lets Cardiff Oncology, Inc. extend the same clinical platform without restarting from zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLead asset: onvansertib\u003c\/li\u003e\n\u003cli\u003ePath: new oncology indications\u003c\/li\u003e\n\u003cli\u003eGoal: broaden value, not category\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple clinical candidates in one pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. has 4 clinical assets in one pipeline: onvansertib, CY140, TROV-054, and TROV-053. That multi-asset setup lets the company develop new products in parallel, which matters for a clinical-stage business that needs a steady flow of next candidates to create value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e4 assets reduce single-asset risk\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eParallel development can speed value creation\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSuccessive candidates help keep the pipeline moving\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiff Oncology Expands Beyond One Drug With 4 Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc.'s product development is the same-market move: onvansertib is being extended into new solid-tumor uses, while CY140, TROV-054, and TROV-053 add fresh oncology combos and targets.\u003c\/p\u003e\n\u003cp\u003eThat keeps the company inside cancer care but broadens value across 4 clinical assets, not one drug.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCY140\u003c\/td\u003e\n\u003ctd\u003eNew target, new product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTROV-054\u003c\/td\u003e\n\u003ctd\u003eNew combo in mCRC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTROV-053\u003c\/td\u003e\n\u003ctd\u003eNew combo in mCRPC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid tumor and leukemia spread\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc.'s CY140 is in Phase 1\/2 studies in both solid tumors and leukemias, so one platform is being tested in two distinct new markets. Solid tumors and leukemias differ in biology, care paths, and endpoints, which makes this a clear diversification move in the Ansoff Matrix. That split matters: the U.S. saw about 2.0 million new cancer cases in 2025, with leukemia a much smaller but separate market segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProstate cancer entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is widening its mix by testing TROV-053 in metastatic castration-resistant prostate cancer, a market with about 313,780 new U.S. cases and 35,770 deaths expected in 2025. That adds a non-colorectal oncology path to the pipeline and lowers reliance on the original lead indication. It also gives Cardiff Oncology, Inc. a shot at a larger second market if the data hold up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eColorectal and prostate program mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology runs two clinical programs at once: metastatic colorectal cancer and metastatic castration-resistant prostate cancer. That gives it a broader development base than a single-disease biotech, so a setback in one indication does not stop the whole pipeline. Both markets are large: the American Cancer Society estimates about 152,810 new colorectal cases and 35,250 prostate deaths in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDistinct PLK target coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. has a broader PLK strategy than a single-target play: PLK1-only and PLK1\/PLK2\/PLK3 coverage create two scientific routes inside one pipeline. That widens the portfolio’s base, because PLK1 is a key mitotic kinase and the PLK family has 3 closely related isoforms, so the company can pursue more than one mechanism-led path. In Ansoff terms, this is diversification through target expansion, not just one asset bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePLK1-only: focused mechanism\u003c\/li\u003e\n\u003cli\u003ePLK1\/2\/3: broader biology\u003c\/li\u003e\n\u003cli\u003eTwo paths reduce single-target risk\u003c\/li\u003e\n\u003cli\u003eWider base can support more programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCombination and monotherapy style pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardiff Oncology’s pipeline is diversified by design: onvansertib is being tested as both a standalone lead agent and in combinations across KRAS-driven cancers, including metastatic colorectal and pancreatic cancer. That split lowers reliance on one product format or one tumor type, while broadening disease exposure across at least 2 active clinical settings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStandalone plus combo development\u003c\/li\u003e\n\u003cli\u003e2+ cancer indications\u003c\/li\u003e\n\u003cli\u003eLower concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiff Oncology Spreads Risk Across 4 Cancer Tracks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCardiff Oncology, Inc. is using diversification in the Ansoff Matrix by pushing one PLK platform into separate diseases, not just one market. Onvansertib is in metastatic colorectal cancer and metastatic castration-resistant prostate cancer, while CY140 is being tested in solid tumors and leukemias. That spreads clinical risk across at least 4 tracks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTrack\u003c\/th\u003e\n\u003cth\u003e2025 case base\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003emCRC\u003c\/td\u003e\n\u003ctd\u003e152,810 U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emCRPC\u003c\/td\u003e\n\u003ctd\u003e313,780 U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSolid tumors + leukemias\u003c\/td\u003e\n\u003ctd\u003e2.0M U.S. cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234164056329,"sku":"crdf-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/crdf-ansoff-matrix.webp?v=1785715780","url":"https:\/\/dcfanalyst.com\/products\/crdf-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}